Fig. 1
CT-26 tumor mice are more sensitive to anti-PD-1 checkpoint blockade than Colon 26 tumor mice. (A) A scheme of in vivo studies for anti-PD-1 antibody across 23 syngeneic tumor models. (B) Growth rate inhibition (%) of anti-mouse PD-1 across 23 syngeneic tumor models of different background mouse strains. (C) Growth and survival of BALB/c mice bearing CT-26 tumors treated with vehicle (PBS), anti-mouse PD-1 and anti-mouse CTLA-4. When the mean tumor volume reached approximately 60 mm3, animals were randomized into treatment groups (n = 10/group) and dosing was initiated on Day 0 of the study. (D) Growth and survival of BALB/c mice bearing Colon 26 tumors treated with vehicle (PBS), anti-mouse PD-1 and anti-mouse CTLA-4. When the mean tumor volume reached approximately 60 mm3, animals were randomized into treatment groups (n = 10/group) and dosing was initiated on Day 0 of the study. (Left) Tumor size as measured by vernier calipers, and the data shown in all panels are the mean (n = 10/group) ± SEM. (Right) Survival curve comparing treatment groups. Mice were euthanized when tumors reached 2000 mm3. n.s., nonsignificant